Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

A sharper focus

The enthusiasm for massive M&A deals is set to redraw industry boundaries

The industry's reawakened enthusiasm for massive M&A deals is set to redraw industry boundaries - particularly if Pfizer is eventually successful with its huge $106bn proposal to acquire AstraZeneca.

There's certainly been no shortage of big deals this month, as the likes of Bristol-Myers Squibb, Lundbeck and Bayer struck out on the acquisition trail.

Perhaps the most intriguing element of this sudden rash of M&A activity was the $16bn Novartis-GlaxoSmithKline 'asset swap', which will see Novartis pick up GSK's oncology portfolio, hand the British company most of its vaccines interests and merge its consumer healthcare business with that of GSK.

The deal will redefine the identity of GSK and Novartis over time and finds further reflection this month in other developments. Merck & Co decided to step away from consumer healthcare, selling its interests in the area - and brands such as Claritin - to Bayer for $14.2bn, and Reckitt Benckiser is considering its pharma future.

Coming after the Abbott/AbbVie and Pfizer/Zoetis splits of the last 18 months, we should expect more of these kinds of deals as companies seek to ruthlessly sharpen their focus.

  • This article was originally published as the editor's comment in PME May 2014


Article by
Dominic Tyer

editorial director of PMGroup

16th May 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics